title: Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
abstract: OBJECTIVE
  To investigate whether serum microRNA-210 (miR-210) level can serve as an indicator of prognosis and a predictor of efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma (HCC).
  
  
  METHODS
  Serum miR-210 level was measured in 113 patients with HCC before transarterial chemoembolization (t1), 3 days after transarterial chemoembolization (t2), and 4 weeks after transarterial chemoembolization (t3) and compared with 39 healthy control subjects. The correlations between miR-210 levels and clinicopathologic factors, tumor responsiveness, and prognosis were analyzed. The modified Response Evaluation Criteria in Solid Tumors assessment was conducted at t3.
  
  
  RESULTS
  A higher mean baseline miR-210 level was observed in patients with HCC compared with control subjects (3.69 ± 2.04 vs 1.08 ± 0.45, P < .001). A positive correlation between baseline miR-210 level and tumor size (P < .001), vascular invasion (P = .005), tumor differentiation (P = .037), and Barcelona Clinic Liver Cancer stage (P < .001) was observed. Elevated baseline miR-210 level also served as an independent prognostic factor predicting poor overall survival (risk ratio, 2.082; P = .003). Patients who did not respond to transarterial chemoembolization had higher baseline miR-210 levels than patients who did respond to treatment (4.34 ± 1.67 vs 3.28 ± 2.15, P < .001). In addition, miR-210 levels increased significantly 4 weeks after transarterial chemoembolization in nonresponders (5.79 ± 2.06 at t3 vs 4.34 ± 1.67 at t1, P < .001), whereas no significant change was observed in responders (3.53 ± 2.20 at t3 vs 3.28 ± 2.15 at t1, P = .116). Lastly, an inverse correlation was identified between miR-210 change t1-t3 with the time to radiologic progression (P < .001).
  
  
  CONCLUSIONS
  Serum miR-210 may represent a novel biomarker for predicting efficacy of transarterial chemoembolization and overall survival for patients with HCC.
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Meixiao
authors.initials: M
authors.lastname: Zhan
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Baoshan
authors.initials: B
authors.lastname: Hu
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Xu
authors.initials: X
authors.lastname: He
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Jianwen
authors.initials: J
authors.lastname: Huang
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
authors.forename: Sirui
authors.initials: S
authors.lastname: Fu
authors.affiliation: Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China. Electronic address: lulg@21cn.com.
authors.forename: Ligong
authors.initials: L
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002454:Cell Differentiation; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000401:mortality; D018450:Disease Progression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C543800:MIRN210 microRNA, human; D035683:MicroRNAs